Lund Melanoma Study Group
21 – 30 of 226
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma with Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
(
- Contribution to journal › Article
-
Mark
Association of metformin use and survival in patients with cutaneous melanoma and diabetes
(
- Contribution to journal › Article
-
Mark
South Africa and the Surgical Diaspora-A Hub for Surgical Migration and Training
(
- Contribution to journal › Article
-
Mark
Caveolin-1 genotypes as predictor for locoregional recurrence and contralateral disease in breast cancer
(
- Contribution to journal › Article
-
Mark
Population-based prognostic instrument (SweMR 2.0) for melanoma-specific survival - An ideal tool for individualised treatment decisions for Swedish patients
(
- Contribution to journal › Article
- 2022
-
Mark
DNA promoter hypermethylation of melanocyte lineage genes determines melanoma phenotype
(
- Contribution to journal › Article
-
Mark
Interplay between Caveolin-1 and body and tumor size affects clinical outcomes in breast cancer
(
- Contribution to journal › Article
-
Mark
Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial
(
- Contribution to journal › Article
-
Mark
Immediate increase in perceived energy after exercise during the course of chemotherapy treatment for breast cancer
(
- Contribution to journal › Article
-
Mark
Dialysis as a Novel Adjuvant Treatment for Malignant Cancers
(
- Contribution to journal › Scientific review